FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
HIGHLIGHTS The US FDA has cleared Amplia’s Investigational New Drug (IND) Application for a clinical trial of narmafotinib in the USA The proposed trial would explore the combination of narmafotinib and FOLFIRINOX in advanced pancreatic cancer patients in the USA MELBOURNE, Australia, Jan. 18, 2024 /PRNewswire/ — Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is […]